pharma QA – Page 30 – Pharma.Tips

CCIT failure in ophthalmic/otic manufacturing: CAPA and sterility assurance controls

Understanding CCIT Failures in Ophthalmic and Otic Manufacturing: An Investigation Approach In the pharmaceutical industry, ensuring product sterility is paramount, particularly when manufacturing ophthalmic and otic products. One critical concern…

Biologic container closure integrity failure after equipment qualification update: viral safety and contamination response plan with inspection-ready evidence

Addressing Failures in Biologic Container Closure Integrity After Equipment Qualification Updates The integrity of container closures in biologics is paramount for ensuring product safety and regulatory compliance. A recent episode…

Stability failure with limited batches during lifecycle management: risk-based GMP justification

“`html Addressing Stability Failures with Limited Batches During Lifecycle Management In the dynamic environment of pharmaceutical manufacturing, stability failures can pose significant risks, particularly when these issues occur with a…

Sterility test failure during aseptic filling: FDA/EMA investigation expectations

Addressing Sterility Test Failures in Aseptic Filling: Investigation Framework and Operational Insights Sterility test failures during aseptic filling can significantly disrupt manufacturing processes, trigger regulatory scrutiny, and lead to product…

Biologic potency drift during commercial manufacturing campaign: investigation strategy aligned to FDA/EMA expectations and comparability principles

Investigating Biologic Potency Drift During Commercial Manufacturing: A Comprehensive Approach Biologic potency drift during a commercial manufacturing campaign can signal underlying issues that may compromise product quality and regulatory compliance.…

Specification justification gap during lifecycle management: CAPA with limited data sets

Managing Specification Justification Gaps in Lifecycle Management: Effective CAPA Strategies In pharmaceutical manufacturing, the lifecycle management of products, especially orphan drugs, presents unique challenges, particularly concerning specification justification gaps. Such…

Fill volume variability after packaging change: batch disposition and patient risk assessment

Investigating Variability in Fill Volume After a Change in Packaging: Batch Disposition and Risk Assessment In the pharmaceutical manufacturing landscape, fill volume variability following a packaging change poses significant challenges.…

Biologic stability failure (real-time/accelerated) during deviation investigation board review: CAPA package with CQA/CPP risk assessment and effectiveness verification

Addressing Biologic Stability Failure During Deviation Investigation Board Review Biologic stability failures, whether occurring during real-time or accelerated testing, present significant challenges to pharmaceutical manufacturers. Such incidents can affect product…

Stability failure with limited batches during small-batch manufacturing: FDA/EMA communication strategy

Addressing Stability Failures in Limited Batches during Small-Batch Manufacturing: An Investigation Approach Stability failures in small-batch manufacturing can pose significant challenges, particularly when regulatory scrutiny increases following deviations or out-of-specification…

CCIT failure during stability pull: CAPA and sterility assurance controls

CAPA and Sterility Assurance Controls Following CCIT Failures in Stability Pulls In the pharmaceutical manufacturing sector, ensuring the integrity and sterility of products is of paramount importance. A recent instance…

Biologic comparability failure after process change during FDA/EMA inspection readiness: CAPA package with CQA/CPP risk assessment and effectiveness verification

Investigation of Biologic Comparability Failures Post-Process Change for Inspection Readiness Pharmaceutical manufacturers face significant challenges when conducting biologic comparability assessments, especially after process modifications. Biologic comparability failure can manifest in…

Method variability OOS during inspection readiness: risk-based GMP justification

Addressing Method Variability Leading to OOS During Inspection Readiness in Pharma During the quality control phase of pharmaceutical manufacturing, method variability can lead to Out of Specification (OOS) results, particularly…